

S3V Vascular Technologies Limited is a medical device company focused on **advanced vascular and neuro solutions**, developing affordable innovations such as **cobalt stents** for **brain clot removal** and **expandable titanium spinal cages**. The company aims to make **minimally invasive stroke and spine treatments** widely accessible by **significantly reducing procedure costs**.

S3V has pioneered low-cost brain clot removal kits, reducing treatment costs from **₹10 lakh** to **₹1 lakh**, received **CDSKO** approval in May 2025 for manufacturing **Class C & D neuro and spine devices**, and is the **first globally licensed company** for an **expandable titanium intervertebral spinal cage**.

Its product portfolio includes **3V Vajra (Expandable Spinal Cage)**, **3V Agile (Oesophageal Stents)**, **3V Astra (Aspiration Catheter)**, **3V Neil (Biodegradable Drug-Eluting Stents)**, **3V Paulo (Balloon Dilatation Catheter)**, and a **Neuro Kit for brain clot removal (from Q4 FY26)**.

Particulars (In INR Cr)	FY25	FY24	Growth
Revenue	17	15	13.3%
EBITDA	2	2.3	-15%
PAT	1	-3.1	132%

Market Size

- The global neurovascular device market is valued at USD 3.1 bn (₹27,900 Cr) in 2025, projected to reach USD 4.0 bn by 2035, growing at a 2.6% CAGR.
- India has an estimated 5 lakh patient base, representing a ₹25,000 Cr opportunity at 50% market share.
- Rising adoption of cobalt stents and neuro devices supports strong export potential.

Last Funding Round

Amount raised: Approximately , ₹110 crore on March, 2024 valuing the company at ₹338 crore

Notable Investors

- L&T Group and Key Management Personnel (KMPs): Significant stake (35+ Cr value).
- Madhu Kela and his team: 25+ Cr investment, providing market access (e.g., Yashoda Hospitals).
- Other notable investors: Utpal Sheth (Rare Enterprises, Rakesh Jhunjhunwala family), Sumit Jalan (Credit Suisse), SBI Mutual Fund, Alchemy Capital, Kotak Pre-IPO Fund.